Body mass index as a prognostic factor in HER-2 positive early breast cancer patients and its effect on duration of treatment with Trastuzumab: A retrospective study

Authors

  • Samaa AbdAlla Bardisi Department of Clinical Oncology and Nuclear Medicine, Kafrelsheikh University, Egypt.
  • Amany Mostafa ElFeky Department of Clinical Oncology and Nuclear Medicine, Kafrelsheikh University, Egypt.
  • Eman Ismail Ibrahim Department of Clinical Oncology and Nuclear Medicine, Zagazig University, Egypt.
  • Yousra Dorgham Department of Clinical Oncology and Nuclear Medicine, Zagazig University, Egypt.
  • Emad Abd Elmongy Sadaka Department of Clinical Oncology and Nuclear Medicine, Kafrelsheikh University, Egypt.

DOI:

https://doi.org/10.47391/JPMA.EGY-S4-51

Keywords:

Prognosis, Breast neoplasms, Trastuzumab, Chemotherapy, Adjuvant, Obesity

Abstract

N/A

Downloads

Published

2023-05-25

How to Cite

Samaa AbdAlla Bardisi, Amany Mostafa ElFeky, Eman Ismail Ibrahim, Yousra Dorgham, & Emad Abd Elmongy Sadaka. (2023). Body mass index as a prognostic factor in HER-2 positive early breast cancer patients and its effect on duration of treatment with Trastuzumab: A retrospective study. Journal of the Pakistan Medical Association, 73(4), S257-S262. https://doi.org/10.47391/JPMA.EGY-S4-51

Issue

Vol. 73 No. 4 (2023): Climate Change and the need for One World One Health

Section

Research Article

License

Copyright (c) 2023 Journal of the Pakistan Medical Association

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.